Hai Pan, PhD
Founder, Chairman & CEO
Weidong Zhong, PhD
President &
Chief Strategy Officer
Xinle Wu, PhD
Chief Scientific Officer &
Head of Research
Martijn Fenaux, PhD
SVP, Nonclinical Development &
Translational Science
Hai Pan, Ph.D.
Founder, Chairman & CEO
Dr. Pan is an accomplished R&D executive and entrepreneur with more than 20 years of industry experience. His track record of success includes advancing over 20 biologics and small molecule drug candidates to clinical development. As founder and CEO of Sciwind Biosciences, Dr. Pan has led the company in building an industry-leading pipeline with an emphasis on treating metabolic disease.
Prior to founding Sciwind Biosciences, Dr. Pan held leadership roles at Amgen, as well as at China-based Kawin Biotech. Dr. Pan is an accomplished researcher with deep knowledge and expertise in drug development for various therapeutic areas, including metabolic disease and infectious disease.
Weidong Zhong, Ph.D.
President & Chief Strategy Officer
Dr. Zhong is a successful biotech entrepreneur, global R&D executive, and distinguished researcher with more than 25 years’ industrial experience. He has delivered over 20 small molecule and biologic drug candidates to clinical development, including marketing authorizations. Prior to joining Sciwind, Dr. Zhong was the founder, CEO, and Chief Scientific Officer of Terns Pharmaceuticals, where he led the company to build a world-class product pipeline for NASH and liver fibrosis and to become publicly listed on NASDAQ (“TERN”) in less than 4 years from its inception.
Prior to founding Terns, Dr. Zhong was the global head of Antiviral Research at Novartis and Senior Director and head of HBV/HCV/liver fibrosis discovery research at Gilead Sciences. During the early part of his career, Dr. Zhong held research leadership positions of increasing responsibilities at Valeant Pharmaceuticals, Schering-Plough Research Institute, and SmithKline Beecham. Dr. Zhong received his Ph.D. in Biochemistry from the University of Wisconsin-Madison and did postdoctoral research at University of California-San Francisco.
Xinle Wu, Ph.D.
Chief Scientific Officer & Head of Research
Dr. Wu has more than 15 years of pharmaceutical industry experience with a strong track record in research and development of innovative medicines. Prior to joining Sciwind Biosciences, Dr. Wu served as Senior Scientific Director at Lilly China Innovation and Partnership and Lilly China R&D Center. Dr. Wu also worked at Amgen as a Principal Scientist.
Dr. Wu received his Ph.D. from Case Western Reserve University and completed his postdoctoral training at University of Texas Southwestern Medical Center.
Martijn Fenaux, Ph.D.
SVP, Nonclinical Development &
Translational Science
Dr. Fenaux has more than 15 years experience as a R&D industry leader, biotech entrepreneur, and researcher. Prior to joining Sciwind Biosciences he co-founded Terns Pharmaceuticals. As Head of Research at Terns he managed the construction of a robust NASH-focused R&D pipeline via internal discovery and in-licensing opportunities. Prior to Terns, Dr. Fenaux led an antiviral discovery group at Novartis. He started his industry career at Gilead Sciences in the HCV antiviral research group, where he was involved in the discovery and early clinical development of multiple drug candidates.
Dr. Fenaux earned his Ph.D. in Molecular Virology from Virginia Tech and completed his postdoctoral training at the Stanford University Medical School.